Amundi Has $18.25 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Amundi decreased its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 4.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 115,418 shares of the medical instruments supplier's stock after selling 5,199 shares during the period. Amundi owned approximately 0.21% of Glaukos worth $18,250,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in Glaukos by 294.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock worth $284,501,000 after acquiring an additional 1,630,270 shares during the last quarter. State Street Corp raised its holdings in Glaukos by 5.3% in the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock worth $254,626,000 after purchasing an additional 98,109 shares during the period. Primecap Management Co. CA boosted its position in shares of Glaukos by 2.0% during the third quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier's stock worth $162,223,000 after purchasing an additional 24,370 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Glaukos by 6.0% during the third quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier's stock worth $152,722,000 after purchasing an additional 66,134 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its holdings in shares of Glaukos by 21.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier's stock valued at $87,776,000 after buying an additional 119,527 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,744 shares of company stock valued at $2,504,131 in the last 90 days. 6.40% of the stock is currently owned by insiders.

Glaukos Stock Up 0.9 %

Glaukos stock traded up $0.93 during mid-day trading on Monday, reaching $103.12. The company's stock had a trading volume of 747,527 shares, compared to its average volume of 578,272. The business's 50 day simple moving average is $140.86 and its 200 day simple moving average is $137.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 12 month low of $85.04 and a 12 month high of $163.71. The company has a market capitalization of $5.83 billion, a price-to-earnings ratio of -35.93 and a beta of 0.99.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. As a group, research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

GKOS has been the topic of several recent analyst reports. Stifel Nicolaus lifted their target price on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, December 31st. UBS Group started coverage on Glaukos in a research report on Friday, December 6th. They set a "buy" rating and a $182.00 price target on the stock. Stephens upgraded Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. Morgan Stanley downgraded shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. Finally, Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and upped their price target for the company from $140.00 to $200.00 in a report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.